| 产品名称： | NCI-BL2122 BL2122 |
|---|---|
| 商品货号： | TS211372 |
| Organism： | Homo sapiens, human |
| Tissue： | peripheral blood |
| Cell Type： | B lymphoblast; Epstein-Barr virus (EBV) transformed |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 2 Cells contain Epstein-Barr Virus (Herpesvirus)
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | Adenocarcinoma |
| Age： | 46 years |
| Gender： | female |
| Ethnicity： | Caucasian |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | NCI-H2122 was derived from pleural effusion from a 46 year old White female with adenocarcinoma of the lung. NCI-BL2122 BL is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as NCI-H2122. |
| Clinical Data： | 46 years
Caucasian female |
| Comments： | The tumor cell line from this patient is available as ATCC CRL-5985. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 5 to 7 x 105 viable cells/mL. A maximum of 1 to 2 x 106 cells/mL is obtainable. Cultures grow as floating aggregates of large cell clusters. Add medium as cell density increases. Double volume approximately every 6 to 7 days. Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
| Cryopreservation： | Culture medium, 95%; DMSO, 5%. Cell culture tested DMSO is available as ATCC Catalog No. 4-X. |
| Culture Conditions： | Temperature: 37°C |
| STR Profile： | Amelogenin: X CSF1PO: 10 D13S317: 9,10 D16S539: 9,12 D5S818: 11,12 D7S820: 8,10 THO1: 7,9.3 TPOX: 9 vWA: 17 |
| Name of Depositor： | AF Gazdar, JD Minna |
| Deposited As： | Homo sapiens |
| References： | NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996. Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | NCI-BL2122 BL2122 |
|---|---|
| 商品货号： | TS211372 |
| Organism： | Homo sapiens, human |
| Tissue： | peripheral blood |
| Cell Type： | B lymphoblast; Epstein-Barr virus (EBV) transformed |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 2 Cells contain Epstein-Barr Virus (Herpesvirus)
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | Adenocarcinoma |
| Age： | 46 years |
| Gender： | female |
| Ethnicity： | Caucasian |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | NCI-H2122 was derived from pleural effusion from a 46 year old White female with adenocarcinoma of the lung. NCI-BL2122 BL is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as NCI-H2122. |
| Clinical Data： | 46 years
Caucasian female |
| Comments： | The tumor cell line from this patient is available as ATCC CRL-5985. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 5 to 7 x 105 viable cells/mL. A maximum of 1 to 2 x 106 cells/mL is obtainable. Cultures grow as floating aggregates of large cell clusters. Add medium as cell density increases. Double volume approximately every 6 to 7 days. Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
| Cryopreservation： | Culture medium, 95%; DMSO, 5%. Cell culture tested DMSO is available as ATCC Catalog No. 4-X. |
| Culture Conditions： | Temperature: 37°C |
| STR Profile： | Amelogenin: X CSF1PO: 10 D13S317: 9,10 D16S539: 9,12 D5S818: 11,12 D7S820: 8,10 THO1: 7,9.3 TPOX: 9 vWA: 17 |
| Name of Depositor： | AF Gazdar, JD Minna |
| Deposited As： | Homo sapiens |
| References： | NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996. Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. |
